KRAS-mutant mCRC urgently needs more (targeted) therapeutic options; patients with these cancers do not respond to the otherwise clinically beneficial strategies blocking the pathway KRAS is involved in signalling [5, 55, 56]. The gene discussed is KRAS; the disease is cancer.